Free Trial

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories logo
$135.41 -1.04 (-0.76%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$136.52 +1.12 (+0.82%)
As of 06/13/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
15

Based on 19 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 4 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for ABT.

Consensus Price Target

$142.59
5.30% Upside
According to the 19 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $142.59. The highest price target for ABT is $160.00, while the lowest price target for ABT is $127.00. The average price target represents a forecasted upside of 5.30% from the current price of $135.41.
Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

Sign Up

ABT Analyst Ratings Over Time

TypeCurrent Forecast
6/14/24 to 6/14/25
1 Month Ago
5/15/24 to 5/15/25
3 Months Ago
3/16/24 to 3/16/25
1 Year Ago
6/15/23 to 6/14/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
7 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$142.59$142.59$137.94$120.64
Forecasted Upside5.30% Upside6.90% Upside8.60% Upside16.37% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.84
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside5.30% Upside6,246.37% Upside14.81% Upside
News Sentiment Rating
Positive News

See Recent ABT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/17/2025Piper Sandler
2 of 5 stars
Adam Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00+9.98%
4/17/2025Raymond James
4 of 5 stars
Jayson Bedford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$132.00 ➝ $142.00+7.70%
4/17/2025Royal Bank of Canada
3 of 5 stars
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$140.00 ➝ $145.00+9.97%
4/17/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Lewis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$117.00 ➝ $127.00-3.32%
4/17/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lawrence Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$136.00 ➝ $147.00+11.90%
4/17/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$158.00 ➝ $159.00+21.71%
4/17/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$135.00 ➝ $145.00+11.76%
4/17/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Taylor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$135.00 ➝ $137.00+5.60%
3/10/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Travis Steed
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$133.00 ➝ $150.00+8.03%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$135.00 ➝ $160.00+15.20%
3/4/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$138.00 ➝ $154.00+9.70%
1/28/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
1/23/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$146.00 ➝ $148.00+25.68%
1/2/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$136.00+19.76%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$133.00 ➝ $138.00+17.37%
10/17/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$115.00 ➝ $130.00+10.34%
10/8/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$130.00+14.69%
9/19/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$131.00+14.04%
7/30/2024Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/21/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:21 PM ET.


Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 13, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to [email protected].

Abbott Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • Abbott Laboratories has received multiple upgrades from analysts, with price targets raised significantly, indicating strong market confidence in the company's future performance.
  • The current stock price is around $135, which is near its 52-week high of $141.23, suggesting potential for further growth.
  • The company reported a solid earnings per share (EPS) of $1.09, exceeding analyst expectations, which reflects strong operational performance.
  • Abbott Laboratories has a healthy net margin of approximately 31.95%, indicating efficient management and profitability.
  • The firm has announced a quarterly dividend of $0.59 per share, providing a steady income stream for investors, with a yield of 1.74%.

Abbott Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • Despite positive earnings, the company's revenue of $10.36 billion was slightly below analyst estimates, which may raise concerns about future growth potential.
  • The stock has a price-to-earnings (P/E) ratio of around 17.77, which could be considered high compared to industry averages, potentially indicating overvaluation.
  • Abbott Laboratories has a beta of 0.73, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • The company has a debt-to-equity ratio of 0.32, which is relatively low, but investors may prefer companies with even lower debt levels for added financial security.
  • With four analysts rating the stock as a hold, there may be a lack of strong bullish sentiment, which could limit upward price movement in the near term.

ABT Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $142.59, with a high forecast of $160.00 and a low forecast of $127.00.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 5.30% based on their 12-month stock forecasts.

Abbott Laboratories has been rated by research analysts at Barclays, Jefferies Financial Group, Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.84 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ABT compares to other companies.


This page (NYSE:ABT) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners
OSZAR »